Vertex Pharmaceuticals Inc
I · Analyse IA
En bref
Vertex develops and sells specialty medicines for serious genetic diseases, primarily cystic fibrosis, sickle cell disease, and beta thalassemia [Company Overview]. The company markets established CF drugs like TRIKAFTA and KALYDECO while expanding into gene therapies (CASGEVY) and pain management (JOURNAVX), selling primarily through specialty pharmacies and hospital networks [Company Overview]. Their pipeline includes early-stage programs targeting Type 1 Diabetes, kidney disease, and rare genetic conditions [Company Overview].
Vertex Pharmaceuticals is a Boston-based biotech company specializing in transformative medicines for serious diseases, with its strongest presence in cystic fibrosis (CF) treatments [Company Overview]. The company generates $12.1B in annual revenue with strong profitability (33% net margin) and maintains fortress-like financial health with net cash exceeding debt [Yahoo Finance]. Recent quarters show revenue growth across multiple product lines including newer launches like CASGEVY for sickle cell disease, reducing reliance on the CF franchise alone [Yahoo Finance].
Vertex demonstrates exceptional financial strength with $110B market cap, robust profitability, and a pristine balance sheet [Yahoo Finance].
Score Sentinellis
9,5/10
En bonne santé financière
Capitalisation boursière
$110,2B
Chiffre d'affaires (12 mois)
$12,1B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
2 articles · classés par pertinence
- Macro2026-05-19
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks
- Macro2026-05-13
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Yahoo Finance
Premium · gratuit avec tout compte
Vertex trades at 25.8x earnings, a modest premium requiring sustained growth to justify valuation, particularly as CF patient population growth eventually plateaus [Yahoo Finance]
Risques
4
Opportunités
4
Signaux d'alerte
1
Direction
10
8 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Vertex Pharmaceuticals Inc
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 4 opportunités et 1 signal d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?